The Assessment of the Stability of Pseudomonas aeruginosa-specific Myoviridae Bacteriophages in Mupirocin and Abukhalsa Burnt Ointments Running title: Combination of Phages and Topical Burn Care Products
Main Article Content
Abstract
Background and Aim: Antibiotic resistance in bacterial infections poses a global health crisis, leading to over 1.27 million annual global deaths in 2019. Pseudomonas aeruginosa is the major cause of healthcare-associated infections, particularly in severe burn cases. The use of lytic phages in a mono- or combination therapy with antibiotics, can be helpful to combat antimicrobial-resistant infections in burn wound patients. This study explores stability in mupirocin and Abukhalsa of three P. aeruginosa-specific characterized and annotated phages (PA45, PA32, PA6) belonging to the Myoviridae group.
Materials and Methods: Each phage was mixed with the mupirocin and Abukhalsa and incubated for 2, 4, and 24 hours at 37°C, with quantification using the agar-overlay method. The results were measured with a one-way analysis of variance statistical method (ANOVA) followed by Holm-Sidak's multiple comparisons test.
Results: The study shows that all three phages were stable above the effective therapeutic titer (ETT) which is considered >107 pfu/mL, with mupirocin more affecting phage activity and retaining efficacy after 24 hours. Notably, Abukhalsa inhibited phage activity even though phages remained active above the ETT after 24 hours.
Conclusion: This study highlights the suitability of mupirocin and Abukhalsa ointments for the studied phages, sustaining their activity beyond the ETT for 24 hours. PA6 and PA32 (jumbo phage) were more stable than PA45 in both ointments tested. These findings emphasize the potency of further investigations for an effective topical combination treatment option in burn wound infections.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.
How to Cite
References
Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol. 2016;64(1):S102-S116. [DOI:10.1016/j.jhep.2016.02.013] [PMID]
Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003. [DOI:10.1136/gut.18.12.997] [PMID] [PMCID]
Le Gal F, Brichler S, Drugan T, Alloui C, Roulot D, Pawlotsky JM, et al. Genetic diversity and worldwide distribution of the Deltavirus genus: A study of 2,152 clinical strains. J. Hepatol. 2017;66(6):1826-41. [DOI:10.1002/hep.29574] [PMID]
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33(2):e00046-19. [DOI:10.1128/CMR.00046-19] [PMID] [PMCID]
Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512-21. [DOI:10.1136/gutjnl-2018-316601] [PMID]
Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677-87. [DOI:10.1093/infdis/jiz633] [PMID] [PMCID]
Amini N, Alavian SM, Kabir A, Aalaei-Andabili SH, Hosseini SYS, Rizzetto M. Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13(1):e8210. [DOI:10.5812/hepatmon.8210]
Sharifzadeh G, Namaei MH, Ebrahimzadeh A. Azarkar Z, Fereidouni M, Bijari B, et al. Prevalence of hepatitis D virus infection and associated factors among HBsAg-positive patients in Birjand, Iran, 2012-2014. Hepat Mon. 2017;17(5):e42866. [DOI:10.5812/hepatmon.42866]
Sayad B, Naderi Y, Alavian SM, Najafi F, Janbakhsh A, Mansouri F, et al. Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. Gastroenterol Hepatol Bed Bench. 2018;11(2):145-52.
Ghadir MR, Belbasi M, Heidari A, Sarkeshikian SS, Kabiri A, Ghanooni AH, et al. Prevalence of hepatitis d virus infection among hepatitis B virus infected patients in qom province, center of iran. Hepat Mon. 2012;12(3):205-8. [DOI:10.5812/hepatmon.5121] [PMID] [PMCID]
Behzadi MA, Leyva-Grado VH, Namayandeh M, Ziyaeyan A, Feyznezhad R, Dorzaban H, et al. Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran. BMC Infect Dis. 2019;19(1):1027. [DOI:10.1186/s12879-019-4661-4] [PMID] [PMCID]
Ahmadi Ghezeldasht S, Hedayati-Moghaddam MR, Mosavat A, Akbarin MM. Sero-Prevalence of Hepatitis D Virus Infection Among Hepatitis B Surface Antigen Positive Patients in Mashhad, Northeastern Iran. Mod Care J. 2019;16(3):e93956. [DOI:10.5812/modernc.93956]
Tahaei SME, Mohebbi SR, Azimzadeh P, Behelgardi A, Sanati A, Mohammadi P, et al. Prevalence of hepatitis D virus in hepatitis B virus infected patients referred to Taleghani hospital, Tehran, Iran. Gastroenterol Hepatol Bed Bench. 2014;7(3):144-50.
Bakhshipour A, Mashhadi M, Mohammadi M, Nezam SK. Seroprevalence and risk factors of hepatitis delta virus in chronic hepatitis B virus infection in Zahedan. Acta Med Iran. 2013;51(4):260-4.
Sharifan P, Amoueian S. Histological and serological epidemiology of hepatitis delta virus coinfection among patients with chronic active hepatitis B virus in Razavi Khorasan Province, northeastern Iran. Iran J Public Health. 2018;47(12):1906-12.
Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000;46(3):420-6. [DOI:10.1136/gut.46.3.420] [PMID] [PMCID]
Roggenbach I, Chi X, Lempp FA, Qu B, Walter L, Wu R, et al. HDV seroprevalence in HBsAg-positive patients in China occurs in hotspots and is not associated with HCV mono-infection. Viruses. 2021;13(9):1799. [DOI:10.3390/v13091799] [PMID] [PMCID]
Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. Viruses. 2021;13(5):830. [DOI:10.3390/v13050830] [PMID] [PMCID]
Lazarus JV, Al‐Rifai A, Sanai FM, Alghamdi AS, Sharara AI, Saad MF, et al. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review. Liver Int. 2022;43(S1):116-123. [DOI:10.1111/liv.15338] [PMID]
Foroutan H, Nemati A, Nasiri-Tosi M, Ghofrani H, Keivani H. Prevalence of hepatitis delta virus infection in various groups with HBVinfection in Tehran, Imam Khomeini Hospital (2005-2006). Med J Islam Repub Iran. 2008;22(2):93-7.
Motamedifar M, Taheri M, Bagheri Lankarani K, Gholami M, Amini Lari M, Faramarzi H, et al. The prevalence and risk factors of hepatitis delta virus in HIV/HBV co-infected patients in Shiraz, Iran, 2012. Iran J Med Sci. 2015;40(5):448-53.
Attaran MS, Sharifi Z, Hosseini SM, Samei S, Ataee, Z. Prevalence of hepatitis B and hepatitis D coinfection in asymptomatic blood donors in Iran. APMIS. 2014;122(3):243-7. [DOI:10.1111/apm.12137] [PMID]
Das K, Ali H, Mahmood T, Munir SM, Ahmed T, Farooq MU. Comparative analysis of disease activity in patients of chronic hepatitis B virus, with and without superinfection with hepatitis D virus; an experience at tertiary care centre. J Ayub Med Coll Abbottabad. 2008;20(2):39-42.
Nwokediuko SC, Ijeoma U. Seroprevalence of antibody to HDV in Nigerians with hepatitis B virus-related liver diseases. Niger J Clin Pract. 2009;12(4):439-42.
Pouri AA, Ghojazadeh M, Baiaz B, Hamzavi FS, Pourasghari B, Somi MH. Prevalence of hepatitis D virus among HBsAg-positive individuals, 2015-2016: Azar cohort study. Health Promot Perspect. 2020;10(1):38-42. [DOI:10.15171/hpp.2020.07] [PMID] [PMCID]
Jedari Seifi S, Sabouri Ghannad M. A study of HDV in HBsAg positive patients in Tabriz, Northwestern Iran. Hepat Mon. 2010;10(2):110-5.
Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol. 2005;20(10):1503-7. [DOI:10.1111/j.1440-1746.2005.03857.x] [PMID]
Khazaee T, Ebrahimzadeh A, Moghaddam E, Ghafori M. Assessment of prevalence and determine infections of hepatitis C and hepatitis D in patients with chronic hepatitis B. Govaresh. 2015;20(4):230-6.
Jedari Seifi S, Gotaslou R, Torabi SE. Seroepidemiology of Hepatitis Delta Virus (HDV), in a Group of Hepatitis B Surface Antigen Positive in Tabriz. Med J Tabriz Uni Med Sciences Health Services. 2010;32(1):33-8.
Roshandel G, Semnani S, Abdolahi N, Besharat S, Keshtkar AA, Joshaqani H, et al. Prevalence of hepatitis D virus infection in hepatitis B surface antigen-positive subjects in Golestan province, northeast Iran. J Microbiol Immunol Infect. 2008;41(3):227-30.